TABLE 1.
Susceptibilities of drugs alone and in combination against 10 clinical isolates of C. albicans by checkerboard microdilution assay
| Drug | Strain | Median MIC (range) of drug (μg/ml) used:
|
|||
|---|---|---|---|---|---|
| Alone
|
In combination
|
||||
| Azole | RAB | Azole | RAB | ||
| FLC | CA1 | 0.25 (0.25-0.5) | 8 | 0.062 (0.062-0.125) | 2 |
| CA2 | 0.5 (0.25-0.5) | 16 | 0.062 (0.062-0.125) | 2 | |
| CA3 | 0.25 (0.25-0.5) | 16 | 0.062 (0.062-0.125) | 4 | |
| CA4 | 1 (0.5-1) | 8 | 0.125 (0.125-0.5) | 1 | |
| CA127 | 1 (0.5-1) | 16 | 0.125 (0.125-0.25) | 4 | |
| CA132 | 0.5 (0.5-1) | 8 | 0.25 | 2 | |
| CA10 | 256 (256-512) | 16 | 0.25 | 2 | |
| CA135 | 128 (64-128) | 16 | 0.25 (0.125-0.25) | 2 | |
| CA137 | 64 (64-128) | 16 | 0.125 (0.125-0.25) | 4 | |
| CA138 | 128 (128-256) | 8 | 0.25 | 2 | |
| KCZ | CA1 | 0.031 (0.031-0.062) | 8 | 0.004 (0.004-0.008) | 2 |
| CA2 | 0.016 (0.016-0.031) | 16 | 0.002 (0.002-0.004) | 2 | |
| CA3 | 0.062 (0.062-0.125) | 16 | 0.004 (0.004-0.008) | 2 | |
| CA4 | 0.062 (0.062-0.125) | 8 | 0.031 (0.031-0.062) | 2 | |
| CA127 | 0.031 (0.031-0.062) | 16 | 0.004 (0.004-0.008) | 8 | |
| CA132 | 0.031 (0.031-0.062) | 8 | 0.004 (0.004-0.008) | 4 | |
| CA10 | 16 | 16 | 0.031 (0.031-0.062) | 4 | |
| CA135 | 16 (8-16) | 16 | 0.002 | 2 | |
| CA137 | 16 (8-16) | 16 | 0.002 | 4 | |
| CA138 | 16 | 8 | 0.062 (0.031-0.062) | 2 | |
| ITR | CA1 | 0.125 (0.125-0.25) | 8 | 0.031 (0.031-0.062) | 4 |
| CA2 | 0.125 (0.125-0.25) | 16 | 0.016 (0.016-0.031) | 4 | |
| CA3 | 0.031 (0.031-0.062) | 16 | 0.004 | 4 | |
| CA4 | 0.031 (0.031-0.062) | 8 | 0.004 | 4 | |
| CA127 | 0.016 (0.016-0.031) | 16 | 0.004 | 2 | |
| CA132 | 0.031 (0.031-0.062) | 8 | 0.016 (0.016-0.031) | 2 | |
| CA10 | 128 (64-128) | 16 | 0.125 (0.125-0.25) | 4 | |
| CA135 | 32 (16-32) | 16 | 0.125 (0.125-0.25) | 4 | |
| CA137 | 16 (16-32) | 16 | 0.125 (0.125-0.25) | 4 | |
| CA138 | 64 (64-128) | 8 | 0.25 | 2 | |